CLSH:OTC-CLS Holdings USA, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.22

Change

0.00 (-0.45)%

Market Cap

USD 0.03B

Volume

0.05M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. The company extracts various cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. Its concentrates are used for electronic cigarettes vaporization, and pharmaceutical and other purposes. The company also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. CLS Holdings USA, Inc. was founded in 2014 and is based in Las Vegas, Nevada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.18 (+0.53%)

USD73.84B 31.03 18.22
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD69.47B 29.23 18.22
TKPHF Takeda Pharmaceutical Company ..

-0.53 (-1.56%)

USD52.78B 31.82 0.10
SFOSF Shanghai Fosun Pharmaceutical ..

-0.45 (-5.88%)

USD23.30B 32.42 4.03
ESALF Eisai Co., Ltd

N/A

USD18.69B 23.92 0.12
ESALY Eisai Co., Ltd

+0.89 (+1.36%)

USD18.49B 21.86 0.12
BAYP Bayport International Holdings..

+0.02 (+1.35%)

USD17.90B N/A N/A
SGIOY Shionogi & Co., Ltd

+0.11 (+0.84%)

USD16.52B 15.88 0.07
SGIOF Shionogi & Co., Ltd

+0.30 (+0.57%)

USD15.66B 15.14 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.83B 900.00 16.02

ETFs Containing CLSH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 48.31% 55% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.31% 55% F 70% C-
Trailing 12 Months  
Capital Gain 181.41% 68% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 181.41% 68% D+ 75% C
Trailing 5 Years  
Capital Gain -76.14% 18% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.14% 18% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 43.06% 65% D 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.06% 64% D 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 217.95% 31% F 21% F
Risk Adjusted Return 19.76% 57% F 46% F
Market Capitalization 0.03B 58% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.36 89% B+ 86% B
Price / Cash Flow Ratio -8.84 70% C- 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -631.73% 9% F 3% F
Return on Invested Capital -10.11% 51% F 25% F
Return on Assets -4.49% 67% D+ 39% F
Debt to Equity Ratio -327.02% 97% A+ 98% A+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.50 37% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector